RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Satisfactory Angiographic and Clinical Outcomes with the Everolimus-Eluting BVS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 30
SP 20
OP 21
DO 10.1177/155989771430015
UL http://mdc.sagepub.com/content/14/30/20.abstract
AB New generation drug-eluting stents (DESs) are increasingly efficient and safe, while the ABSORB everolimus-eluting bioresorbable vascular scaffold (BVS) is thought to reduce long-term complications, including neoatherosclerosis and very late stent thrombosis. The objective of the Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stent trial [EVERBIO II; NCT01711931] was to compare the efficacy of the BVS with the best-in-class new generation DESs.